Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600Emutated metastatic colorectal cancer.

被引：0
|
作者：
Chen, Yungchang
Li, Xiaoqian
Man Yuxin
Hu, Hai
Wang, Liyang
Zhang, Zhixuan
Chen, Ping
Liu, Yang
Lu, Jin
Lin, Tongyu
机构：
[1] Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Sichuan Canc Hosp & Inst, Chengdu, Peoples R China
[2] Shandong Acad Med Sci, Shandong Canc Hosp, Dept Med Oncol, Jinan 250117, Peoples R China
[3] Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Dept Pathol,Sichuan Canc Hosp & Inst, Chengdu, Sichuan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
156
引用
收藏
页码：156 / 156
页数：1
相关论文
共 50 条
  • [31] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
    Eriksen, Martina
    Pfeiffer, Per
    Rohrberg, Kristoffer Staal
    Yde, Christina Westmose
    Petersen, Lone Norgard
    Poulsen, Laurids Ostergaard
    Qvortrup, Camilla
    [J]. BMC CANCER, 2022, 22 (01)
  • [32] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
    Martina Eriksen
    Per Pfeiffer
    Kristoffer Staal Rohrberg
    Christina Westmose Yde
    Lone Nørgård Petersen
    Laurids Østergaard Poulsen
    Camilla Qvortrup
    [J]. BMC Cancer, 22
  • [33] Encorafenib plus cetuximab treatment in BRAF V600-Emutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series
    Hafliger, Emilie
    Boccaccino, Alessandra
    Lapeyre-Prost, Alexandra
    Perret, Audrey
    Gallois, Claire
    Antista, Maria
    Pilla, Lorenzo
    Lecomte, Thierry
    Scartozzi, Mario
    Soularue, Emilie
    Salvatore, Lisa
    Bourgeois, Vincent
    Salati, Massimiliano
    Tougeron, David
    Evesque, Ludovic
    Vaillant, Jean-Nicolas
    El-Khoury, Reem
    Lonardi, Sara
    Cremolini, Chiara
    Taieb, Julien
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 168 : 34 - 40
  • [34] BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs, choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer
    Kopetz, S.
    Crothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Gollerkeri, F.
    Maharry, K.
    Loupakis, F.
    Hong, Y.
    Steeghs, F.
    Guren, T.
    Arkenau, H.
    Garcia Alfonso, P.
    Sandor, V.
    Christy-Bittel, J.
    Anderson, L.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [35] A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy
    Williams, Casey B.
    McMahon, Caitlin
    Ali, Siraj M.
    Abramovitz, Mark
    Williams, Kirstin A.
    Klein, Jessica
    McKean, Heidi
    Yelensky, Roman
    George, Thomas J., Jr.
    Elvin, Julia A.
    Soman, Salil
    Lipson, Doron
    Chmielecki, Juliann
    Morosini, Deborah
    Miller, Vincent A.
    Stephens, Philip J.
    Ross, Jeffrey S.
    Leyland-Jones, Brian
    [J]. ONCOTARGETS AND THERAPY, 2015, 8 : 3561 - 3564
  • [36] BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
    Liu, Junjia
    Xie, Hao
    [J]. CANCERS, 2023, 15 (18)
  • [37] Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E-Mutation Positive Metastatic NSCLC
    Fan, Y.
    Jianying, Z.
    Yuanyuan, Z.
    Yan, Y.
    Nong, Y.
    Juan, L.
    Jialei, W.
    Jun, Z.
    Zhehai, W.
    Jun, C.
    Zhu, T.
    Li, H.
    Li, Z.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S423 - S423
  • [38] Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
    Long, Georgina V.
    Weber, Jeffrey S.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Daud, Adil
    Gonzalez, Rene
    Sosman, Jeffrey A.
    Hamid, Omid
    Schuchter, Lynn
    Cebon, Jonathan
    Kefford, Richard F.
    Lawrence, Donald
    Kudchadkar, Ragini
    Burris, Howard A., III
    Falchook, Gerald S.
    Algazi, Alain
    Lewis, Karl
    Puzanov, Igor
    Ibrahim, Nageatte
    Sun, Peng
    Cunningham, Elizabeth
    Kline, Amy S.
    Buono, HeatherDel
    OpattMcDowell, Diane
    Patel, Kiran
    Flaherty, Keith T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (08) : 871 - +
  • [39] Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study
    Buzaid, Antonio C.
    Mathias, Clarissa de Cerqueira
    Perazzo, Florencia
    Simon, Sergio D.
    Fein, Luis
    Hidalgo, Jorge
    Murad, Andre M.
    Esser, Regina
    Senger, Stefanie
    Lerzo, Guillermo
    [J]. CLINICAL COLORECTAL CANCER, 2010, 9 (05) : 282 - 289
  • [40] Safety of encorafenib, binimetinib, plus cetuximab for Japanese patients with BRAF V600E metastatic colorectal cancer
    Yamaguchi, Toshifumi
    Daisuke, Kotani
    Atsuo, Takashima
    Takeshi, Kato
    Toshiki, Masuishi
    Yoshito, Komatsu
    Manabu, Shiozawa
    Taito, Esaki
    Naoki, Izawa
    Shinji, Takeuchi
    Hideaki, Bando
    Satoru, Iwasa
    Hiroko, Hasegawa
    Taroh, Satoh
    Hiroya, Taniguchi
    Takayuki, Yoshino
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S479 - S479
12345